Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Get Free Report) was the target of a large decline in short interest in the month of September. As of September 15th, there was short interest totalling 384,900 shares, a decline of 48.5% from the August 31st total of 746,800 shares. Based on an average daily volume of 2,570,000 shares, the short-interest ratio is currently 0.1 days. Currently, 0.5% of the shares of the company are short sold.
Unicycive Therapeutics Price Performance
Shares of UNCY stock opened at $0.42 on Friday. The company has a market capitalization of $39.33 million, a P/E ratio of -0.35 and a beta of 2.34. The company’s 50-day simple moving average is $0.38 and its two-hundred day simple moving average is $0.76. Unicycive Therapeutics has a one year low of $0.20 and a one year high of $1.82.
Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.08. On average, research analysts expect that Unicycive Therapeutics will post -0.26 EPS for the current fiscal year.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on Unicycive Therapeutics
Institutional Trading of Unicycive Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new position in shares of Unicycive Therapeutics during the first quarter valued at about $36,000. Rosalind Advisors Inc. acquired a new stake in shares of Unicycive Therapeutics in the first quarter worth $2,594,000. Finally, BVF Inc. IL lifted its holdings in shares of Unicycive Therapeutics by 70.5% in the 1st quarter. BVF Inc. IL now owns 3,611,601 shares of the company’s stock valued at $4,984,000 after buying an additional 1,493,462 shares during the period. Hedge funds and other institutional investors own 40.42% of the company’s stock.
Unicycive Therapeutics Company Profile
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Read More
- Five stocks we like better than Unicycive Therapeutics
- Learn Technical Analysis Skills to Master the Stock Market
- CarMax’s Impressive Rally: What Investors Should Watch Next
- What Is WallStreetBets and What Stocks Are They Targeting?
- MarketBeat Week in Review – 9/23 – 9/27
- Stock Splits, Do They Really Impact Investors?
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.